An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?

CNS Oncol. 2019 Dec 1;8(4):CNS47. doi: 10.2217/cns-2019-0017. Epub 2019 Dec 10.

Abstract

Aim: We investigated uptake of short-course chemo-radiotherapy and compared outcomes with other treatment schedules in elderly patients with glioblastoma (GBM). Methods: Patients aged 65 or over with a diagnosis of GBM were identified from an 18-month period from three centers in the UK. The primary end point of this study was overall survival from the date of diagnosis. Results: The analysis included 210 patients. Overall median survival was 5.0 months. Approximately 31.9% of patients received combined chemoradiation; multivariate analysis showed that patients who received standard chemoradiation were at a reduced risk of death than those receiving hypofractionated chemoradiation. Discussion: In this retrospective study, patients treated with standard chemoradiation experienced better outcomes than patients receiving hypofractionated chemoradiation. Patient selection likely contributed to these findings.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Brain Neoplasms / mortality
  • Brain Neoplasms / therapy*
  • Chemoradiotherapy
  • Clinical Trials as Topic
  • Disease Management
  • Female
  • Glioblastoma / mortality
  • Glioblastoma / therapy*
  • Humans
  • Male
  • Retrospective Studies
  • Survival Analysis
  • United Kingdom